Canada markets close in 4 hours 32 minutes
  • S&P/TSX

    20,220.91
    +40.31 (+0.20%)
     
  • S&P 500

    4,298.07
    +0.93 (+0.02%)
     
  • DOW

    34,077.79
    +165.35 (+0.49%)
     
  • CAD/USD

    0.7767
    +0.0014 (+0.18%)
     
  • CRUDE OIL

    87.40
    -2.01 (-2.25%)
     
  • BTC-CAD

    30,641.06
    -602.53 (-1.93%)
     
  • CMC Crypto 200

    566.80
    -5.12 (-0.90%)
     
  • GOLD FUTURES

    1,791.60
    -6.50 (-0.36%)
     
  • RUSSELL 2000

    2,007.78
    -13.56 (-0.67%)
     
  • 10-Yr Bond

    2.8480
    +0.0570 (+2.04%)
     
  • NASDAQ

    13,072.28
    -55.77 (-0.42%)
     
  • VOLATILITY

    19.99
    +0.04 (+0.20%)
     
  • FTSE

    7,543.46
    +34.31 (+0.46%)
     
  • NIKKEI 225

    28,868.91
    -2.87 (-0.01%)
     
  • CAD/EUR

    0.7632
    +0.0007 (+0.09%)
     

Marvel Biosciences Initiates Formulation Development with Catalent

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.

Catalent, one of the world's largest contract research organizations, has begun development of novel solid amorphous dispersion formulations of MB-204, the Company's novel adenosine A2a receptor antagonist. A new formulation could allow for the administration of even lower doses of the drug and further improve the safety of the product.

"Having a formulation ready for pre-clinical toxicology and clinical trials is another vital milestone the company needs to achieve in order to conduct its first-in-human studies," said Dr. Mark Williams, Chief Science Officer of Marvel. "Catalent is a world-class company with deep expertise in this area, and we look forward to working with them on this project."

Marvel's lead compound asset, MB-204 ("MB-204"), is being developed to help treat neurological conditions such as depression and anxiety, Alzheimer's, ADHD and NASH. Marvel's compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson's disease drug Istradefylline (Nourianz®). Both Istradefylline and MB-204 are highly active derivatives of caffeine, which act as antagonists of the adenosine A2a receptor ("A2aR"). Caffeine is the most widely consumed psychoactive drug in the world and has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration.

About Catalent, Inc.

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products annually. Catalent's expert workforce exceeds 18,000, including more than 2,500 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2468
Email: info@marvelbiotechnology.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119438

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting